Richard D. Baird

Learn More
PURPOSE This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K). PATIENTS AND(More)
A dose-escalation, phase I study evaluated the safety, pharmacokinetics, pharmacogenomics, and efficacy of ES-285, a novel agent isolated from a marine mollusc, in adult cancer patients. Patients received a 24-hour i.v. infusion of ES-285 once every 3 weeks until disease progression or unacceptable toxicity. The starting dose was 4 mg/m(2). Dose escalation(More)
More women die from breast cancer across the world today than from any other type of malignancy. The clinical course of breast cancer varies tremendously between patients. While some of this variability is explained by traditional clinico-pathological factors (including patient age, tumor stage, histological grade and estrogen receptor status), molecular(More)
BACKGROUND High circulating tumor cell (CTC) counts are associated with poor prognosis in several cancers. Enrollment of patients on phase I oncology trials requires a careful assessment of the potential risks and benefits. Many patients enrolled on such trials using established eligibility criteria have a short life expectancy and are less likely to(More)
PURPOSE KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) and allosteric AKT inhibitors (such as MK-2206), the combination of which may overcome resistance to both monotherapies. EXPERIMENTAL DESIGN We conducted a dose/schedule-finding(More)
Running title: Targeting KRAS signalling through MEK and AKT. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 2 Preliminary data were presented in part as oral and poster presentations at the 47th and 48th and may hold stock/stock options in the company. JMS, PS, and ML were employees of AstraZeneca,(More)
This document presents life cycle costs for a low-level radioactive disposal facility and a comparable assured isolation facility. Cost projections were based on general plans and assumptions, including volume projections and operating life, provided by the Connecticut Hazardous waste Management Service, for a facility designed to meet the State's needs.(More)
The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in which the morphological and molecular characteristics of the originating tumor are preserved through passaging in the mouse. An integrated platform(More)
The optimized assured isolation facility (AIF) consists of waste shipping containers being placed inside steel-reinforced concrete overpacks, which are, in turn, placed in steel-reinforced concrete vaults without an earthen cover system. The concrete vaults are designed to remain in service for hundreds of years, with the aid of ongoing active maintenance.(More)
PURPOSE Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. METHODS Cohorts A (normal renal function: creatinine clearance [CrCL] >80 mL/min/1.73 m2), B (moderate renal impairment:(More)